Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl TAIFUN for breakthrough cancer pain
2004-001620-21Phase 2Completed
- Sponsor
- LAB Pharma
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fentanyl in breakthrough cancer pain (BTcP) (4 arms), sponsored by LAB Pharma. Primary endpoints: Sum of Pain Intensity Difference (SPID) and Responder rate. Started Oct 2004; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2004-001620-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001620-21.